1. Bristol Myers to build first cell therapy factory in Europe — Teva CEO Schultz sees a 35% raise despite company's legal woes — Why Biogen Q1 earnings weren't good enoughSee more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

future neuro line?

Discussion in 'NuVasive' started by Anonymous, May 8, 2012 at 7:16 PM.

  1. Anonymous

    Anonymous Guest

    With NuVasive being a strong spine company, any chance of them adding a neuro plating/instrument line to their portfolio? That said, any chance of them adding ANY type of product line outside of spine? I know their are always rumors of them being acquired and added to another company's portfolio, any legitimacy to that?
  2. Anonymous

    Anonymous Guest

    Nobody is going to add Nuvasive to their portfolio. They have nothing of substance. Too much debt. Medtronic Lawsuit cost them too much, and they may end up owing even more as they appeal that. They haven't paid that liability yet, under appeal. Their end cost will therefor be higher on that.

    What they got was developed/picked from UC Davis, the State of California gave Nuvasive it's product/technique. Unless UC Davis comes up with something new, I don't see Nuvasive adding anything to their line up.

    They won't offer anything outside of spine. They don't fund R&D. Unless UC Davis develops something and it's walked off to Nuva. That's a possibility.
  3. Anonymous

    Anonymous Guest

    Nuva's 1st Quarter report:

    """Our annual effective income tax rate for 2012 is expected to be higher than the U.S. federal statutory rate of 35% primarily due to state income taxes, net of federal benefit, estimates for certain non-deductible expenses, and FOREIGN LOSSES expected to be incurred for which no benefit can be recorded."""


    ---They show for now a 56% Income Tax Rate

    """We expect expenses recorded in connection with the amortization of intangible assets to continue to increase in absolute dollars for the foreseeable future as amortization of acquired in-process research and development commences once acquired research and development projects reach technological FEASIBILITY."""

    The courts made them put money into escrow that they owe for their lawsuits...which they are appealing. If they have to pay it out:

    """""which could negatively impact our liquidity and our ability to invest in and run our business on an ongoing basis.""""


    """""The general condition of the financial markets and the economy has exacerbated those risks and may affect the value of our current investments and restrict our ability to access the capital markets or even our own funds.""""

    They show an increase in 1st Quarter Net Cash Flow due to:
    """" ......a refund of $11.2 million relating to an overpayment at December 31, 2011"""

    .....ummmm so they doubled their books cash flow over last years 1st quarter.....by overpaying something in December....genius. Certainly justifies their current stock price..

  4. Anonymous

    Anonymous Guest

    that's a deeper analysis than i wanted, but i get your point. i feel all these device companies have some sort of huge pending lawsuits or other form of really bad publicity yet their business contiues on. how many companies out there are still around that you thought would be gone by now?! LOTS!! jnj/depuy...what a hit they are taking with their hip implant troubles but yet they are doing business as usual at all of my hospitals. yes, every region is different but hopefully you see my point. so, regardless of what negativity nuvasive is going through, i don't see that stopping them from being acquired or expanding their portfolio(s).
  5. Anonymous

    Anonymous Guest

    Depuy won't survive it's hip implant failure.

    They are only pushing on right now because all of the Liability for the lawsuits against them is still a few years off. There are over 6,000 cases filed against them in court right now. They aren't worried because they don't pay 1 penny until after the last court appeal...many years off.

    Johnson & Johnson is spending big bucks paying for positive news articles in British medical journals to try to limit overseas liability...but it won't work.

    There's 1 Federal Class Action where they're trying to get as many of the 40,000 hip users in America under...Federal Class Actions wipe away company liability and poor crippled citizens get nothing...lawyers get all the money. They won't get everyone under the Federal Class Action and all those people outside of the class action will kill Depuy along with overseas liabilities.

    Depuy's just being ridden along for a couple more years...its dead. Unless their hopes that court filers die... limits their losses pays off. It could, its a gamble they are taking.
  6. Anonymous

    Anonymous Guest

    With that said. NuVa is in hot water. Medtronic is seeking more damages in the recent lawsuit. It would appear NuVa lawyers are not so good in this one. I like the stock going up in this spectulation but what is to come of the Nuva portfolio if Medtronic crushes them?
  7. Anonymous

    Anonymous Guest

    Why did NUVA stock go up?

    Borrowed money and bam, stock went up. Notes were to be paid in 2014 and 2017. All of the sudden there were millions of their stock being traded.

    Look at the last few hours. Down to only 100 stocks:


    They aren't paying off that 2017 Note for the money they borrowed.
  8. Anonymous

    Anonymous Guest

    Uhhh.....why does this say for NUVA stock that 101% of the available stock is Institutionally owned?


    When for Caterpillar for example only 65% of the available stock is owned by the company....

    Something smells funny....
  9. Anonymous

    Anonymous Guest

    You pointed out something interesting....how can 101% of the traded stock be Institutionally owned? Means they have more paper out than they should? Had more trades going than allowed? Since there are NUVA employees with company stock under their belts...it's impossible for 101% of NUVA's stock to be 'Institutionally Owned".....unless EVERYONE ditched their NUVA stock.

    Either way it looks like they fixed it, showing 96% of all their stock as being Institutionally owned.

    EPS (Earnings Per Share) = -1.78.

    They are paying lots of people to hype their stock, with stories of Investor Hypers rating it "outperform" at the beginning of the month. Looks like everyone laughed at them.
  10. Anonymous

    Anonymous Guest

    Nate "The Rock" Quarry the MMA Fighter is a paid speaker for Nuvasive.

    Uhhh looks like his XLIF surgery didn't help because his Twitter Feed says he just had ANOTHER spine surgery.

    In March he had a very emotional display on Spike TV saying he's out of the sport for GOOD and won't be coming back.

    Don't look good for Nuvasive....or XLIF
  11. Anonymous

    Anonymous Guest

    Poor guy! You hate that he had to have another surgery. I will bet that it may have been the wrong surgery from the get go. Who knows! I hope Nuvasive pays for this one too. Nate seems like a good guy but just allowed Nuvasive to kiss his ass for too long. Get well Nate and I wish you the best. He speaks well enough and seems to be on his game with the media so maybe a spokesman for MMA on TV. Good Luck.
  12. Anonymous

    Anonymous Guest

    Oh snap! Nate Quarry's Twitter says he went to CYPRUS to get another spine surgery.

    Now that's SAD! Think Nuvasive's going to keep paying him as a spokesman?
  13. Anonymous

    Anonymous Guest

    Cyprus = Stem Cells
  14. Anonymous

    Anonymous Guest

    Cyprus = AIMIS

    It's a new push to get overseas use of Nuvasive products. Notice they aren't using the word 'XLIF' and are using the new term "MIS" (Minimally Invasive Spine)?

    Looks like Nuvasive's footing the bill to send their Surgeons to Cyprus to work at AIMIS for around ten days while on vacation over there. Trying to get the UK/Middle East spine patient load with the AIMIS project in Cyprus.